Tioconazole
Tioconazole, Vagistat (tioconazole) is a small molecule pharmaceutical. Tioconazole was first approved as Tz-3 on 1983-02-18. It is used to treat mycoses and vulvovaginal candidiasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Tioconazole, Vagistat (discontinued: Tz)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| basic care tioconazole | ANDA | 2024-12-18 |
| careone tioconazole 1 | ANDA | 2024-12-18 |
| dg health tioconazole 1 | ANDA | 2021-05-11 |
| equaline tioconazole 1 | ANDA | 2023-07-24 |
| equate tioconazole 1 day | ANDA | 2025-08-11 |
| foster and thrive tioconazole | ANDA | 2023-10-25 |
| good sense tioconazole 1 | ANDA | 2023-12-19 |
| leader ticonazole | ANDA | 2021-06-23 |
| leader tioconazole 1 | ANDA | 2025-02-19 |
| monistat tioconazole 1 | ANDA | 2019-03-19 |
Show 9 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| vulvovaginal candidiasis | EFO_0007543 | D002181 | B37.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AC: Imidazole and triazole derivatives, topical antifungals
— D01AC07: Tioconazole
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AF: Imidazole derivatives, gyncological antiinfectives
— G01AF08: Tioconazole
HCPCS
No data
Clinical
Clinical Trials
150 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Onychomycosis | D014009 | — | B35.1 | — | — | 2 | — | — | 2 |
| Candidiasis | D002177 | — | B37 | — | — | 1 | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 1 | 2 |
| Mycoses | D009181 | — | B35-B49 | — | — | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tioconazole |
| INN | tioconazole |
| Description | 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole is a member of the class of imidazoles that comprises 2-(2,4-dichlorophenyl)ethylimidazole carrying an additional (2-chloro-3-thienyl)methoxy substituent at position 2. It is an ether, a member of imidazoles, a member of thiophenes and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 |
Identifiers
| PDB | — |
| CAS-ID | 65899-73-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200438 |
| ChEBI ID | 77898 |
| PubChem CID | 5482 |
| DrugBank | DB01007 |
| UNII ID | S57Y5X1117 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Tioconazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 867 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,296 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use